In conclusion, the present study allowed identifying a novel positive regulatory link between HNF4α (MODY1) and GIP incretin in the intestine and paves the way for further studies as to whether this molecular relationship may be therapeutically exploited in metabolism disorders including diabetes. Here, GIP is linked to Other metabolic disease.